Future Directions for the Management of HR+ Breast Cancer
Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.
Read More
ES HR+ Breast Cancer: CDK4/6 Inhibitors in Clinical Practice
A discussion on the use of adjuvant CDK4/6 inhibitors in clinical practice for the treatment of early stage HR+ breast cancer.
Read More
Using CDK4/6 Inhibitors in Early Stage HR+ Breast Cancer
Experts in breast cancer share insights on the role of CDK4/6 inhibition in the adjuvant setting for early stage HR+ breast cancer.
Read More
Early Stage HR+ Breast Cancer: Optimizing Multigene Assays
Hope S. Rugo, MD, leads the discussion on the new data presented at the 2021 ASCO annual meeting for MammaPrint and Breast Cancer Index for early stage HR+ breast cancer.
Read More
Using Genomic Assays for Early Stage HR+ Breast Cancer
The role of genomic assays, including Oncotype DX as reported on in the RxPONDER trial, for the optimal management of early stage HR+ breast cancer is discussed.
Read More
Emerging Agents for the Management of HR+ mBC
Aditya Bardia, MD, MPH, leads the discussion on the use of novel CDK4/6 inhibitors, BCL2 inhibitors, and oral SERDS for the treatment of HR+ metastatic breast cancer.
Read More
PI3KCA Inhibition: Managing AEs in HR+ mBC
Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, review the optimal management of adverse events associated with alpelisib in HR+ metastatic breast cancer.
Read More
Using CDK4/6 Inhibitors After HR+ mBC Disease Progression
Breast cancer experts comment on whether there is a benefit to switching to or continuing on CDK4/6 inhibitors with disease progression for HR+ metastatic breast cancer and discuss the use of tamoxifen for third-line endocrine therapy.
Read More
Case Discussion: Resistance to CDK4/6 Inhibitors in HR+ mBC
Andrew D. Seidman, MD, presents a case study of a 56-year-old postmenopausal woman diagnosed with stage IIB HR+ breast cancer and leads the discussion on approaching treatment for the given patient.
Read More
Implications of PIK3CA Mutations in HR+ mBC
Dejan Juric, MD, leads the discussion on the role of PIK3CA mutations in HR+ metastatic breast cancer.
Read More
SOLAR-1 and CBYL719X2101: Alpelisib + Fulvestrant in HR+/HER2-/PIK3CA-Mutated Advanced Breast Cancer
July 9th 2021Nicholas McAndrew, MD, MSCE, reviews PIK3CA mutations in HR+/HER2- breast cancer and provides his perspective on the joint analysis of SOLAR-1 and CBYL719X2101 in which patients were given alpelisib and fulvestrant.
Read More
Selecting a CDK4/6 Inhibitor for HR+ mBC
Experts in breast cancer comment on the appropriate patient selection of CDK4/6 inhibitors for the management of HR-positive metastatic breast cancer.
Read More
Using CDK4/6 Inhibitors in First-Line Treatment of HR+ mBC
A review of data from key phase 3 clinical trials, including ASCO 2021 updates, assessing the use of CDK4/6 inhibitors with endocrine therapy for the frontline treatment of HR-positive metastatic breast cancer.
Read More
Management of HR+ mBC: Key Prognostic Factors
Considerations for approaching the treatment of HR-positive metastatic breast cancer through insights on key prognostic factors.
Read More
Role of Molecular Profiling in HR+ Metastatic Breast Cancer
Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, discuss when it is appropriate to order molecular testing and the impact of testing on the treatment of HR-positive metastatic breast cancer.
Read More